Wall Street analysts forecast that AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) will report earnings per share of ($0.32) for the current quarter, according to Zacks. Zero analysts have made estimates for AEterna Zentaris’ earnings. AEterna Zentaris reported earnings per share of ($0.46) in the same quarter last year, which suggests a positive year over year growth rate of 30.4%. The company is expected to announce its next earnings report on Thursday, August 9th.
According to Zacks, analysts expect that AEterna Zentaris will report full-year earnings of ($0.05) per share for the current year. For the next fiscal year, analysts expect that the firm will post earnings of ($0.37) per share. Zacks’ EPS averages are an average based on a survey of analysts that cover AEterna Zentaris.
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its quarterly earnings data on Monday, May 7th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.96. The company had revenue of $24.66 million for the quarter, compared to analyst estimates of $2.00 million. AEterna Zentaris had a negative return on equity of 106.80% and a net margin of 6.95%.
AEterna Zentaris traded down $0.03, reaching $2.12, during midday trading on Friday, Marketbeat Ratings reports. The stock had a trading volume of 1,841 shares, compared to its average volume of 348,208. The firm has a market capitalization of $36.33 million, a P/E ratio of -1.56 and a beta of 0.98. AEterna Zentaris has a 52-week low of $0.89 and a 52-week high of $3.29.
About AEterna Zentaris
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.